Global shares ended mostly on a down note - Thursday Review, November 19

Global shares ended mostly on a down note - Thursday Review, November 19

The American benchmarks reversed losses amid talks about a new stimulus package

The US

The rising number of COVID-19 infections seems to have put the stimulus package back on the table. The benchmarks reacted positively to the news, leaving behind the high number of unemployment claims. USA30 went up 0.18%, while USA500 rose 0.36%. TECH100 gained 0.87%.

Crude oil traded 0.8% lower at $41.66 per barrel.

Gold fell 1% to $1,855 per ounce.

The Dollar Index closed at 92.575.

Asia and Australia

The news regarding AstraZeneca’s vaccine was overshadowed by the new restrictions meant to curb the COVID-19 infections.

HongKong45 fell 0.77%.

Japan225 lost 0.77%.

Down under, Australia200 closed 0.17% lower.

Europe

Despite AstraZeneca's positive data regarding its experimental COVID-19 vaccine, the markets ended in the red. Germany30 and UK100 each traded 0.9% lower. France40 lost 0.8%.

Brent oil inched 0.5% lower to $44.11 a barrel.

EUR/USD traded at 1.1831 after losing 0.2%.

Sources: investing.com, reuters.com

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.